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Abstract: The study aimed to assess the reliability of the scores, evidence of validity, and feasibility 
of the Frail-VIG index. A validation study mixing hospitalized and community-dwelling older peo-
ple was designed. Intraclass correlation coefficient (ICC) was used to assess the inter-rater agree-
ment and the reliability. The construct validity of the Frail-VIG index with respect to the Frailty 
Phenotype (FP) was evaluated by calculating the area under the receiver operating characteristic 
curve (AUC-ROC). Convergent validity with the Clinical Frailty Scale (CFS) was assessed using 
Pearson’s correlation coefficients. The feasibility was evaluated by calculating the average time re-
quired to administer the Frail-VIG index and the percentage of unanswered responses. A sample of 
527 older people (mean age of 81.61, 56.2% female) was included. The inter-rater agreement and 
test–retest reliability were very strong: 0.941 (95% CI, 0.890 to 0.969) and 0.976 (95% CI, 0.958 to 
0.986), respectively. Results indicated adequate convergent validity of the Frail-VIG index with re-
spect to the FP, AUC-ROC 0.704 (95% CI, 0.622 to 0.786), and a moderate to strong positive correla-
tion between the Frail-VIG index and CFS (r = 0.635, 95% CI, 0.54 to 0.71). The Frail-VIG index ad-
ministration required an average of 5.01 min, with only 0.34% of unanswered responses. The Frail-
VIG index is a reliable, feasible, and valid instrument to assess the degree of frailty in hospitalized 
and community-dwelling older people. 




Over the last few decades, developed countries have undergone a demographic and 
epidemiological shift that has led to progressive aging of the population and to an in-
creased prevalence of people with chronic diseases [1,2]. While the two most prevalent 
chronic health problems are multimorbidity and frailty [3], frailty is the chronic condition 
most frequently associated with poor health outcomes, such as mortality or disability 
[4,5], as has become apparent during the COVID-19 pandemic [6,7]. In this scenario, the 
concept of frailty—understood as a vulnerability state against stressing factors due to lim-
ited compensatory mechanisms [8]—seems to emerge as a sound line of argument for 
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health systems and their professionals, which require understandable narratives and 
pragmatic instruments [9,10]. However, despite the widespread consensus regarding the 
usefulness of the concept of frailty [11] and the need for its routine assessment in the clin-
ical practice [12], there is still some controversy over the operational approach to address 
it [8]. 
These difficulties may be explained by two facts. On the one hand, the broadness of 
the concept of frailty (which ranges from the syndromic view to the accumulation of def-
icits approach) [13], in addition to the enriching academic debate, may have determined 
difficulties in its applicability to the healthcare practice. In summary, it can be said that 
frailty may be presented as a syndromic/dichotomous reality (“Is this person frail or not?”) 
[14], which becomes especially useful for screening for the population that can potentially 
benefit from preventive actions; the Frailty Phenotype (FP) [14] criteria, the Fatigue, Re-
sistance, Ambulation, Illnesses, and Loss of Weight (FRAIL) [15] questionnaire, the Géron-
topôle Frailty Screening Tool [16], or functional performance tests (such as the gait speed 
test [17] or the Short Physical Performance Battery [18]) are examples of useful instru-
ments for this approach. However, frailty can also be seen as a continuous reality based 
on the accumulation of different deficits (“How frail is this person?”) [19], which is particu-
larly useful to assess a person’s situational diagnosis or degree of reserve [20]. Both the 
Clinical Frailty Scale (CFS) [21] and the frailty indices (FIs) [22] may be effective instru-
ments in this approach to frailty. 
On the other hand, there are many frailty assessment tools available [12], which are 
not always sufficiently pragmatic or feasible in the daily clinical practice, or which are not 
valid or reliable enough [23]. In this sense, the psychometric assessment of frailty instru-
ments should be a research priority, in order to produce even stronger evidence on the 
practical usefulness of the concept of frailty [24,25]. This need becomes especially relevant 
in the case of FIs [26], for which there are limited studies on reliability of its scores, con-
struct validity, and feasibility [27]. 
One of the FIs that has shown better mortality predictive capacity is the Frail-VIG 
index, with an area under the receiver operating characteristic curve (AUC-ROC) of 0.90 
and 0.85 at 1 and 2 years, respectively [28,29]. Published in 2017 by Amblàs-Novellas et 
al., this FI, based on the Comprehensive Geriatric Assessment, consists of 22 trigger ques-
tions that are used to assess 25 deficits from eight different dimensions, with a final score 
that can range from 0 to 1 (with the submaximal limit in the clinical practice being close 
to 0.7). There is an excel calculator available at https://en.c3rg.com/index-fragil-vig. (31 
March 2021) 
1.2. Objective/Rationale 
Although previous papers have shown an excellent mortality predictive capacity, as 
well as good content validity and interpretability, there are no conclusive data on its reli-
ability, construct validity, and feasibility. Therefore, this article aims to analyze the relia-
bility of the scores, evidence of validity, and feasibility of the Frail-VIG index. 
2. Methods 
This article follows the guidelines established by the Consensus-Based Standards for 
the Selection of Health Measurement Instruments (COSMIN) on the design of studies to 
assess the measurement properties of instruments [30]. The study protocol was approved 
by the Ethics Committee of the University Hospital of Vic (2018958/PR189). 
2.1. Study Design and Participants 
This is an observational study, based on the classical test theory [31] and conducted 
in the prospective FIS/VIG cohort designed for the validation of the Frail-VIG index and 
the dynamic assessment of frailty over time. Participant recruitment was performed at an 
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intermediate care hospital, with a home-based follow-up of 12 months and quarterly as-
sessments of the degree of frailty by means of the Frail-VIG index. 
The inclusion criteria for the study were individuals ≥75 years of age and/or identi-
fied as people with complex care needs (PCC, in Catalan) or with palliative care needs 
(MACA, in Catalan), based on the criteria developed by the Health Department of Cata-
lonia [32,33], who were admitted to the Santa Creu de Vic University Hospital (Barcelona, 
Spain) during the study enrolment period (July 2018–July 2019). This intermediate care 
hospital was equipped with 100 beds, as well as subacute care, functional rehabilitation, 
palliative care, and psychogeriatric units. Patients were admitted from primary care or 
acute care hospitals, generally in the context of an acute intercurrent process. Those indi-
viduals for whom the in-person home follow-up was deemed difficult due to geographical 
reasons (more than 30 km away from the hospital) were excluded from the study. 
2.2. Variables and Data Sources 
In terms of epidemiological variables, these included age, gender, and usual place of 
residence. At the clinical level, all the variables included in the Frail-VIG index (Table 1) 
were collected, as well as the degree of frailty according to the classification into four cat-
egories commonly used in our clinical practice: non-frailty (Frail-VIG index score < 0.2), 
mild frailty (Frail-VIG index score 0.2–0.35), moderate frailty (Frail-VIG index score 0.36–
0.5), and severe frailty (Frail-VIG index score > 0.5). 
The collection of data at the time of hospitalization was conducted by the hospital’s 
healthcare professionals (physicians and nurses), with the Frail-VIG index being an in-
strument used in the regular clinical practice at the Geriatrics and Palliative Care units. 
Home follow-up upon discharge was performed by four research nurses combining face-
to-face visits (months 1, 6, and 12) and telephone visits (months 3 and 9). 
Table 1. Epidemiological and clinical characteristics of the cohort at baseline and at the 6 and 12 
month follow-ups. At the 6 month follow-up (when the different frailty measurement instruments 
were compared), the characteristics of the group of non-frail (Frail-VIG index 0–0.19) vs. frail indi-




N = 527 
Month 6 
Follow-Up Month 12 
Follow-Up 
n = 176 
Total 
n = 200 
No Frailty 
n = 20 
(10.0%) 
Frailty 
n = 180 
(90.0%) 
Demographic characteristics  
Age (years), mean ± SD 81.61 ± 9.9 
80.9 ± 
10.6 
82.6 ± 7.2 80.7 ± 10.9 81.7 ± 9.6 
Sex (women), N (%) 296 (56.2) 114 (57.0) 11 (55.0) 103 (57.2) 98 (55.7) 
Usual habitat, No (%) 
Nursing home 68 (12.9) 63 (31.5) 0 (0.0) 63 (35.0) 48 (27.3) 
Home 440 (83.5) 129 (64.5) 20 (100.0) 109 (60.5) 111 (63.1) 
Others 2 (0.4) 1 (0.5) 0 (0.0) 1 (0.6) 0 (0.0) 
Missing information 17 (3.2) 7 (3.5) 0 (0.0) 7 (3.9) 17 (9.6)  
Living arrangement 1, No (%) 
With family 303 (68.5) 93 (71.6) 15 (75.0) 78 (70.9) 76 (68.5) 
With caregiver 22 (5.0) 6 (4.6) 0 (0.0) 6 (5.5) 5 (4.5) 
Alone 105 (23.8) 25 (19.2) 4 (20.0) 21 (19.1) 18 (16.2) 
Others 4 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Missing information 8 (1.8) 6 (4.6) 1 (5.0) 5 (4.5) 12 (10.8) 
Frail-VIG variables 
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Functional IADLs (0–3), mean 
± SD 
1.48 ± 1.3 1.81 ± 1.2 0.15 ± 0.3 1.99 ± 1.1 1.80 ± 1.3 
Barthel index (0–100), mean ± 
SD 
73.87 ± 27.5 
57.5 ± 
32.4 
90.5 ± 22.5 53.9 ± 31.3 62.2 ± 31.1 
Malnutrition, N (%) 144 (27.3) 34 (17.1) 2 (10.0) 32 (17.9) 15 (9.1) 
Cognitive impairment, N (%) 198 (37.6) 83 (41.7) 0 (0.0) 83 (46.3) 62 (37.8) 
Depressive syndrome, N (%)  165 (31.3) 78 (39.6) 2 (10.0) 76 (42.9) 75 (44.9) 
Insomnia/anxiety, N (%) 255 (48.4) 119 (59.8) 4 (20.0) 115 (64.2) 96 (56.8) 
Social vulnerability, N (%) 74 (14.0) 4 (2.0) 0 (0.0) 4 (2.0) 8 (4.8) 
Delirium, N (%) 85 (16.1) 59 (29.5) 1 (5.0) 58 (32.2) 45 (26.8) 
Falls, N (%) 111 (21.1) 35 (17.7) 1 (5.0) 34 (19.1) 23 (13.9) 
Ulcers, N (%) 56 (10.6) 27 (13.5) 0 (0.0) 27 (15.0) 17 (10.4) 
Polypharmacy, N (%) 425 (80.6) 176 (88.0) 357 (86.7) 176 (88.0) 141 (83.9) 
Dysphagia, N (%) 88 (16.7) 41 (20.6) 0 (0.0) 41 (22.9) 28 (17.2) 
Pain, N (%) 131 (24.9) 62 (31.0) 2 (10.0) 60 (33.3) 36 (21.7) 
Dyspnoea, N (%) 47 (8.9) 34 (17.1) 1 (5.0) 33 (18.4) 21 (12.8) 
Cancer, N (%) 128 (24.3) 43 (21.8) 2 (10.0) 41 (23.2) 25 (15.3) 
Chronic respiratory disease, N 
(%) 
147 (27.9) 78 (39.4) 3 (15.0) 75 (42.1) 63 (37.3) 
Chronic cardiac disease, N (%) 232 (44.1) 111 (55.5) 6 (30.0) 105 (58.3) 89 (53.9) 
Chronic neurological disease, 
N (%) 
74 (14.1) 47 (23.5) 2 (10.0) 45 (25.0) 34 (20.5) 
Chronic digestive disease, N 
(%) 
40 (7.6) 39 (20.1) 2 (10.0) 37 (21.2) 28 (17.2) 
Chronic renal disease, N (%) 210 (39.8) 91 (46.4) 3 (15.8) 88 (49.8) 68 (40.7) 
Frailty degree 2 
Total cohort average, mean ± 
SD 
0.31 ± 0.15 
0.39 ± 
0.16 
0.11 ± 0.05 0.42 ± 0.14 0.35 ± 0.16 
No frailty, N (%) 115 (21.8) 20 (10.0) 20 (100.0) - 35 (20.5) 
Mild frailty, N (%) 190 (36.1) 52 (26.0) - 52 (28.9) 43 (25.1) 
Intermediate frailty, N (%) 147 (27.9) 77 (38.5) - 77 (42.8) 59 (34.5) 
Severe frailty, N (%) 75 (14.2) 51 (25.5) - 51 (28.3) 34 (19.9) 
1 Refers to patients not living in a nursing home. 2 The frailty degree was calculated using the cate-
gorization of the Frail-VIG index into no frailty (Frail-VIG index score <0.2), mild frailty (Frail-VIG 
index score 0.2–0.35), moderate frailty (Frail-VIG index score 0.36–0.5), and advanced frailty (Frail-
VIG index score >0.5). IADLs, Instrumental Activities of Daily Living; SD, standard deviation. 
2.3. Psychometric Assessment of the Frail-VIG Index 
This study evaluated the following psychometric parameters: reliability of the scores, 
evidence of construct validity, and feasibility. The evaluation was performed at different 
time points (Figure 1). 




Figure 1. Cohort follow-up timeline, showing the psychometric characteristics assessed at the different moments of the 
follow-up (as well as the statistical methodology used to assess it). 
2.3.1. Reliability 
Reliability is the extent to which scores for people who have not changed are the same 
for repeated measurement under several conditions [34]. Following COSMIN recommen-
dations, the following measures were assessed: (A) inter-rater reliability, by different per-
sons on the same occasion, evaluated by administering the Frail-VIG index with respect 
to the individual’s baseline situation by two different teams: the geriatrics professionals 
(physicians and/or nurses) responsible for admission, and by the team responsible for 
hospitalization of that individual, which was performed blindly (without having the re-
sult of the test performed by the other team); (B) test–retest reliability, over time: in this 
case, the four nurses administered the Frail-VIG index on two separate occasions for about 
a week in a blind manner (without having the results of the previous test), ensuring sim-
ilar conditions to the baseline measurement (assessing, in particular, the absence of any 
added concurrent processes). For the assessment of frailty, the calculation of the internal 
consistency of the Frail-VIG index was dismissed upon considering it not relevant, given 
that it was developed as a formative model (in which the items together form the con-
struct) and not as a reflective model (in which all items are a manifestation of the same 
underlying construct) [35]. 
2.3.2. Validity 
Since previous studies published on the Frail-VIG index have already demonstrated 
evidence of its content validity and its criterion validity related to mortality [28,29], as well 
as its convergent discriminative validity related to the EQ-5D-3L index, this study focused 
on evidence of construct validity between the Frail-VIG index and other frailty measure-
ment tools. To this end, the Frail-VIG index was administered at the same time and in the 
same subjects at the cohort’s 6 month follow-up, together with the following tools: 
 As a categorical instrument for the assessment of frailty (frail vs. not frail), the five 
original FP criteria based on the physical characteristics as reported in the original 
Cardiovascular Health Study by Fried were used: weight loss, exhaustion, low en-
ergy, expenditure, slow walking speed, and weak grip strength [36]. The JAMAR 
PLUS+ Hand Dynamometer was used to assess grip strength, assessing the average 
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score of two grips of the grip strength of the dominant hand. Those with no charac-
teristics were identified as fit, those with one or two characteristics were identified as 
pre-frail, and those with three to five characteristics were identified as frail. 
 CFS [21], a validated ordinal measure of frailty based on nine category clinical de-
scriptors and pictographs ranging from one (fit) to nine (terminally ill), was used as 
a tool to assess continuous frailty. 
Although frailty indices assess frailty as a continuous variable, different cutoffs have 
been proposed in the literature to distinguish between non-frail and frail individuals (≥0.2 
[37] vs. ≥0.25 [12]); in some cases, a distinction has also been proposed for non-frail indi-
viduals (≤0.08), pre-frail individuals (0.09–0.24), and frail individuals (≥0.25), even weigh-
ing the FI result according to the individual’s chronological age [38]. 
2.3.3. Feasibility 
Feasibility measures whether a questionnaire is affordable for use in the environment 
in which it is intended to be used, and it should be a usual feature in frailty measurements, 
while also being simple to apply [39]. The two most frequently used measurements are 
the calculation of percentage of unanswered responses and the time required to adminis-
ter the measure. To assess the percentage of unanswered responses, the total number of 
tests performed since the start of the study to the 12 month follow-up was analyzed. To 
assess the time of administration of the Frail-VIG, the duration of the 12 month home 
follow-up was timed. Other aspects to consider when assessing feasibility based on COS-
MIN recommendations that have been incorporated into this study are the education or 
training required to administer each test, the need for special equipment/devices, and the 
physical space required [40]. 
2.4. Statistical Methods 
Categorical variables are described as frequencies. Quantitative variables are shown 
as the mean and standard deviation (SD) when the distribution was normal, and as medi-
ans with 25th and 75th percentiles when the distribution was asymmetric. We considered 
a p-value <0.05 as statistically significant. The data were analyzed using the latest available 
version of the IBM SPSS Statistics 27 software. 
2.4.1. Reliability 
Reliability was assessed using the intraclass correlation coefficients (ICCs) (two-way 
random) for the inter-rater agreement and test–retest reliability, as well as Bland–Altman 
plots for their graphical representation. We calculated a minimum requirement of 40 sub-
jects [41], who were randomly selected. ICCs greater than or equal to 0.70 were interpreted 
as optimal [34]. 
2.4.2. Validity 
In accordance with COSMIN recommendations, we used the AUC-ROC as the 
method of choice for the assessment of the convergent validity of the Frail-VIG index (con-
tinuous score) with respect to the FP (noncontinuous score). AUC-ROCs of < 0.70, 0.70–
0.89, and ≥ 0.90 were considered poor, adequate, and excellent, respectively[42]. While 
there is no gold-standard tool for the assessment of frailty [34], most frailty tools have 
ended up conducting comparative studies with FP, since it was the first published tool 
and represented a benchmark for the other initiatives. Thus, for the calibration of the Frail-
VIG index with respect to FP, the prevalence of frail individuals was assessed using both 
instruments, as well as the sensitivity, specificity, positive and negative predictive value, 
and Youden index for different cutoffs for the identification of a condition of frailty (≥ 
0.20, ≥ 0.23 and ≥ 0.25). We also analyzed the discriminative validity of the Frail-VIG index 
by comparing it between people classified as frail and non-frail using the FP. We 
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hypothesized that people classified as frail would have a substantially higher average in-
dex than non-frail people. 
On the other hand, the convergent validity between the two continuous score instru-
ments (CFS and Frail-VIG index) was evaluated using Pearson’s correlation coefficients. 
We expected moderate to strong positive correlations (r ≥ 0.50) between the measurement 
instruments. 
2.4.3. Feasibility 
Feasibility was evaluated by calculating the average and SD of time required to ad-
minister Frail-VIG, as well as the percentage of unanswered responses. To evaluate the 
time of administration of the Frail-VIG index, a minimum requirement of 40 subjects [41] 
was estimated, which were randomly selected. 
3. Results 
3.1. General Characteristics 
A total of 527 individuals were enrolled: 296 (56.2%) women and 231 (43.8%) men, 
with a mean (SD) age of 81.6 (9.9) years. Table 1 shows the demographic and clinical char-
acteristics of the cohort at the time of enrolment in the study (corresponding to the base-
line Frail-VIG index, administered by the team responsible for hospitalization of the sub-
jects), and at the 6 and 12 month follow-ups (administered by the nurses conducting fol-
low-up). 
3.2. Psychometric Results of the Frail-VIG Index 
3.2.1. Reliability 
The inter-rater reliability by the two professionals corresponding to the baseline 
Frail-VIG of the 41 individuals assessed was ICC 0.941 (95% IC, 0.890 to 0.969)—Figure 
2A. The test–retest reliability for the 51 individuals assessed was ICC 0.976 (95% CI, 0.958 
to 0.986)—Figure 2B. Both results suggest excellent reliability. 
 
Figure 2. Bland–Altman correlation for the inter-rater reliability (A) and test–retest reliability (B). 
3.2.2. Validity 
All of the 6 month follow-up subjects were included (n = 200). Losses to follow-up 
with respect to the initial cohort (n = 527) corresponded to (1) deaths (227), of which 136 
died during hospitalization, mainly (65.4%) in the palliative care unit, (2) definitive losses 
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to follow-up (n = 39), (3) and occasional losses to follow-up (n = 62), who were later fol-
lowed up at 9 months. 
Table 2 shows the prevalence of frail individuals in the 6 month follow-up cohort 
using the FP and the Frail-VIG index for the different cutoffs proposed in the literature 
(between 0.2 [37] and 0.25 [12]). 
When assessing the construct validity of the Frail-VIG index with respect to FP, the 
AUC-ROC was 0.704 (95% CI, 0.622 to 0.786) (Figure 3), consistently with an adequate 
convergent validity. Table 3 shows the sensitivity, specificity, positive and negative pre-
dictive value, and Youden index for different cutoffs. The Youden index presented its best 
score (0.43) for the cutoff of the Frail-VIG index at a ≥0.20. 
Table 2. Prevalence of frail people in the cohort using Frailty Phenotype (FP), as well as different 
cutoffs of the Frail-VIG index. 
  Non-Frailty/Pre-Frailty Frailty 
FP 
No (%) 52 (26.0) 148 (74.0) 
Frail-VIG, mean ± SD 0.30 (0.16) 0.42 (0.15) 
IF-VIG No (%) 20 (10) 180 (90) 
(Frailty cutoff ≥0.20) Frail-VIG, mean ± SD 0.11 (0.05) 0.42 (0.14) 
IF-VIG No (%) 32 (16) 168 (84) 
(Frailty cutoff ≥0.23) Frail-VIG, mean ± SD 0.14 (0.06) 0.44 (0.13) 
IF-VIG mean ± SD 45 (22.5) 155 (77.5) 
(Frailty cutoff ≥0.25) Frail-VIG, mean (DS) 0.17 (0.07) 0.45 (0.12) 
 
Figure 3. Graphical representation of the ROC plot of the Frail-VIG index, for the people identified 
as frail according to the Frailty Phenotype criteria. 
Table 3. Sensitivity, specificity, and positive and negative predictive value between the Frail-VIG 
index and the Frailty Phenotype (FP). 
 Sensitivity Specificity PPV NPV Youden Index 
Frail-VIG Index (Frailty 
Value Cutoff) 
FP 
78.3% 65.0% 95.3% 25.0% 0.43 ≥0.20 
79.8% 56.3% 90.5% 34.6% 0.36 ≥0.23 
79.4% 44.4% 83.1% 38.5% 0.24 ≥0.25 
NPV, negative predictive value; PPV, positive predictive value. 
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The correlation coefficient between the two continuous score instruments (Frail-VIG 
index and CFS) for the calculation of their convergent validity showed moderate to strong 
positive correlation between the Frail-VIG index and CFS (r = 0.64, 95% CI, 0.54 to 0.71) 
(Figure 4). 
 
Figure 4. Scatter plots of the correlation between the Frail-VIG index and Clinical Frailty Scale. 
3.2.3. Feasibility 
Of the 2273 tests performed during the first year of follow-up (equivalent to 50,006 
variables; 22 variables for each test), the number of missing variables was 170. This is 
equivalent to 0.34%. Supplementary File 1 includes the number of losses of variables in 
the Frail-VIG index administered in a hospital setting (baseline situation, admission, and 
discharge) and in the follow-up at community level (1, 3, 6, 9, and 12 months). Losses in 
this follow-up period at 6 and 12 months correspond to deaths (n = 55) or losses to follow-
up (n = 19). The administration time of 68 individuals was evaluated, with an average of 
5.01 min (SD 2.86). 
With respect to the more qualitative aspects, a two-session training was conducted 
for the interviewers, who also had an instruction manual available. For the administration 
of the Frail-VIG index, no special equipment or physical space was required. In the context 
of this study, a dynamometer (for grip strength assessment) was only required for the 
evaluation of convergent validity, as well as a 4 m space and a chronometer to calculate 
gait speed. 
4. Discussion 
The results obtained support the Frail-VIG index as a reliable, feasible, and valid tool 
to assess the degree of frailty in hospitalized and community-dwelling older people. 
4.1. Psychometric Assessment of the Frail-VIG Index 
There are limited high-quality reliability, validity, and feasibility data for many of 
the FI tools. A recent systematic review of the psychometric characteristics of multicom-
ponent tools designed to assess frailty in older adults found that, for example, there were 
reliability and validity data available for only 21% of the tools [27]. This could be ex-
plained by the fact that, as opposed to the Frail-VIG index, many of the frailty assessment 
tools were developed and tested retrospectively using data available from large-scale lon-
gitudinal studies or were developed in conjunction with a larger trial whose main aim 
was not the development of a frailty assessment tool [27]. 




The reliability of the Frail-VIG index scores can be classified as very strong. There are 
virtually no previous studies on the reliability of FI [43], which makes it difficult to com-
pare the results obtained. With respect to other frailty instruments, the Frail-VIG index 
showed better inter-rater reliability (0.94) than, for example, the Edmonton Frail Scale 
(0.77) [44] or the CFS (from 0.97 [21] to 0.68 [45]). 
Test–retest was also excellent (0.97), indicating that if frail elderly people are stable 
and the Frail-VIG index is administered under similar conditions, their scores remain sta-
ble over time. These results are as good as or better than those published for other assess-
ment instruments, such as the CFS (0.87), the Tilburg Frailty Indicator (0.79) [46], or the 
FRAIL questionnaire (0.71) [47]. 
4.1.2. Validity 
Convergent validity between Frail-VIG index and FP was substantial (0.70), similar 
to the results previously published by other FIs (0.65) [26]. When the dichotomized Frail-
VIG index for the different cutoffs proposed by the literature was compared with the FP, 
better results of the Youden index were obtained for values ≥0.20, which would endorse 
it as a cutoff for considering someone frail when using the Frail-VIG index. For this cutoff, 
the Frail-VIG index showed an overall higher sensitivity (78.3%) than other FIs (45.9 to 
60.7%), but a lower specificity (65.0% vs. 83.5 to 90.0%) [26]. However, this assessment of 
the FIs from a dichotomic perspective is likely to have academic importance rather than 
clinical implications; clearly, the two measures (FI vs. FP) cannot be considered equiva-
lent, since they are different instruments with different objectives, and the combined/se-
quential use of both instruments is advisable, as they provide different and complemen-
tary clinical information on the individual’s condition [13,48]. 
Lastly, the degree of correlation between the two instruments that assess frailty as a 
continuous reality, Frail-VIG index and CFS (r = 0.66), was similar to previous studies for 
these two instruments (r = 0.71) [49]. This is consistent with published evidence on con-
vergent validity between CFS and other FIs, ranging from 0.59 of the electronic frailty 
index [50] to 0.91 of the FI used by Chong et al. [51]. 
4.1.3. Feasibility 
In terms of feasibility, most published studies used administration time as the most 
common measure, ranging from 44 s for the CFS to 5 to 20 min for the Fried Phenotype 
[4,52]. In the case of the FI, in the FI-CGA [53], the administration time ranges from 10 [54] 
or 12.5 min [55] to 25 min [56]. The CSHA-FI [21] requires about 20–30 min [12]. In fact, 
the time required for the administration of the FIs has been mentioned by some authors 
as one of the main limitations to their implementation in routine clinical practice [57]. 
Thus, the Frail-VIG index would fall in the low range of time of administration of the 
frailty indices, probably as a result of the lower number of variables involved (22), com-
pared, for example, with the more than 30 items of the different versions of the CSHA-FI 
[21]. There are not many studies either on the completion rate of FI forms. In the study 
conducted by Lin et al. [55], a completion rate of 45% was found for the FI-CGA, with the 
majority (91%) of the incomplete forms having minimal amount of data missing—fewer 
than four items. In this sense, the low number of missing data in our study is remarkable. 
Lastly, the Frail-VIG index does not require any additional equipment or space, which has 
sometimes proven an obstacle to the use of CP, GSFT, and some other versions of the FI 
[55]. 
4.2. Limitations of the Study 
The main limitations of the study are probably related to the generalizability of its 
results; on the one hand, the inclusion criteria determined a relatively large sample of 
individuals, with a significant degree of frailty. On the other hand, even though this is an 
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instrument designed to be used by both physicians and nurses in all settings, in this study, 
it was used by geriatrics specialists, who are very familiar with the use of the Frail-VIG 
index (commonly used in clinical practice in our environment). Thus, for instance, in the 
assessment of feasibility, both the time of administration of the Frail-VIG index and the 
low number of missing data could also be explained by the expertise of the professionals 
involved (there is probably a learning curve in its use by professionals), as well as the 
thoroughness inherent to the context of a research study. 
Another limitation to bear in mind is that not all psychometric properties were as-
sessed in all settings and by all professional profiles. Therefore, for example, reliability 
and inter-rater reliability were assessed in hospital settings by physicians and nurses, 
while the test–retest has been performed in a community setting by the follow-up nurses. 
Thus, more studies are needed to evaluate the psychometric properties in daily clinical 
practice by other professionals in different settings and populations. 
4.3. Healthcare Implications and Future Research 
It is essential to have reliable, valid, and feasible tools to take advantage of the mul-
tiple opportunities offered by the assessment of frailty as a central element of clinical prac-
tice, research, and planning in the care of the elderly [9,12,58], ranging from the prevention 
of disability to the care of individuals with complex and palliative care needs [20,39]. Un-
fortunately, only 5% of the frailty assessment tools have shown evidence of reliability and 
validity that was within statistically significant parameters and of fair methodological 
quality [27]. 
There are two areas of special interest for future research, which are related to the 
multidimensional nature of the IF and the assessment of the dynamic behavior of frailty. 
In the first place, the validity of the content of the instruments should be enhanced with 
respect to physical, cognitive-psychological, and social frailty [59,60]. In the second place, 
the serial administration of the Frail-VIG index in a prospective cohort is likely to provide 
knowledge on the different courses of frailty [61], as well as on the ability of this FI to 
assess sensitivity to change and responsiveness, understood as the ability of an instrument 
to distinguish clinically important changes as the result of an intervention [34]. Further 
studies are also needed to continue to advance in the validation process of the Frail-VIG 
index, especially with respect to its cross-cultural validity and generalizability. 
5. Conclusions 
According to the COSMIN guidelines, the results obtained endorse the Frail-VIG in-
dex as a reliable, feasible, and valid instrument. Firstly, a very strong reliability of the 
scores was found in its administration among different professionals (inter-rater reliabil-
ity), as well as in test–retest reliability. Secondly, the Frail-VIG showed a moderate to 
strong positive correlation with CFS, as well as adequate convergent validity with respect 
to the FP. This also allowed calibrating the Frail-VIG index for the identification of frail 
individuals, establishing a frailty threshold at a score of ≥0.20. Lastly, excellent feasibility 
has been observed in relation to the time of administration, with respect to the few items 
missed, and due to the lack of specific space or equipment requirements. 
All these characteristics, together with their good correlation, with the mortality 
demonstrated in previous studies, and with the discriminating capacity between the dif-
ferent degrees of frailty, make the Frail-VIG index a particularly interesting tool to assess 
frail elderly people in hospitalized and community-dwelling settings. 
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